← Back to patent-cliff list
Iadademstat
Tier C — Watch / tradeIadademstat
Oryzon Genomics Sa
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：LSD1
Indications (approved)：Acute myeloid leukaemia, Myelofibrosis, Myeloproliferative neoplasm, 骨髓增生异常-骨髓增生性疾病, Essential thrombocythaemia, Polycythaemia vera, Lung cancer, Small cell lung cancer
Regional status
US
Phase II
2022-12-21
EU
No progress
2016-12-20
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Iadademstat?
Approved indications include: Acute myeloid leukaemia, Myelofibrosis, Myeloproliferative neoplasm, 骨髓增生异常-骨髓增生性疾病, Essential thrombocythaemia, Polycythaemia vera, Lung cancer, Small cell lung cancer.
When does the Iadademstat patent expire?
No public expiry year is available for Iadademstat yet; this page updates once verified.
How do I get a quote for Iadademstat intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-03